Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genomics BioSci & Tech CoTPE:4195 +0.33%42 PB Ratio is 2.36 as of Aug. 09, 2026, which is 28% below its 10-year median of 3.29. GuruFocus rates TPE:4195 with a GF Score™ of 42/100 and a GF Value™ of NT$34.15 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,225 Biotechnology companies, Genomics BioSci & Tech Co ranks better than 58.12% on this metric.
Genomics BioSci & Tech Co Ltd stock PB Ratio (=2.36) is close to 2-year low of 2.3.
The historical rank and industry rank for Genomics BioSci & Tech Co's PB Ratio or its related term are showing as below:
TPE:4195'
s PB Ratio Range Over the Past 10 Years
Min: 2.3 Med: 3.29 Max: 5.44
Current: 2.36
During the past 13 years, Genomics BioSci & Tech Co's highest PB Ratio was 5.44. The lowest was 2.30. And the median was 3.29.
TPE:4195's PB Ratio is ranked better than 58.12% of 1225
companies
in the Biotechnology industry
Industry Median: 2.94
vs TPE:4195: 2.36
During the past 3 years, the average Book Value Per Share Growth Rate was -16.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -9.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -3.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Genomics BioSci & Tech Co was 19.50% per year. The lowest was -16.70% per year. And the median was 0.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Genomics BioSci & Tech Co PB Ratio Related Terms
Genomics BioSci & Tech Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genomics BioSci & Tech Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomics BioSci & Tech Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genomics BioSci & Tech Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Genomics BioSci & Tech Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Genomics BioSci & Tech Co (TPE:4195) has a PB Ratio of 2.36 as of Aug. 09, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Genomics BioSci & Tech Co and its competitors. This is 28% below median its historical median of 3.29. Over the past decade, Genomics BioSci & Tech Co's PB Ratio has ranged from 2.30 to 5.44. According to the industry distribution chart, Genomics BioSci & Tech Co ranks #513 out of 1225 companies in the Biotechnology industry, placing it in the top 41.9%.
Is Genomics BioSci & Tech Co's PB Ratio too high?
Genomics BioSci & Tech Co's current PB Ratio of 2.36 is 28% below median its 10-year median of 3.29. Over the past 10 years, this metric has ranged from a low of 2.30 to a high of 5.44. The Biotechnology industry median PB Ratio is 2.94. Genomics BioSci & Tech Co's value of 2.36 is 19.7% below this industry median. Based on the distribution chart, Genomics BioSci & Tech Co ranks #513 out of 1225 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Genomics BioSci & Tech Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Genomics BioSci & Tech Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genomics BioSci & Tech Co ranks #513 out of 1225 companies for PB Ratio. This puts Genomics BioSci & Tech Co in the upper half of its industry. The industry median PB Ratio is 2.94. Genomics BioSci & Tech Co's value of 2.36 is 19.7% below this benchmark. Historically, Genomics BioSci & Tech Co's own PB Ratio has ranged from 2.30 to 5.44 over the past decade. While the company's 10-year median is 3.29 vs. the industry median of 2.94, Genomics BioSci & Tech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.94, based on 1,225 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomics BioSci & Tech Co's current PB Ratio of 2.36 is 19.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Genomics BioSci & Tech Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomics BioSci & Tech Co's current PB Ratio is 2.36, which is 28% below median its own 10-year median of 3.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomics BioSci & Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Genomics BioSci & Tech Co (TPE:4195) is currently considered Possible Value Trap. The stock's GF Value™ is NT$34.15, compared to a current price of NT$15.35 — trading 55.1% below its estimated fair value. The current PB Ratio is 2.36, which is 28% below median its 10-year median of 3.29 and 19.7% below the Biotechnology industry median of 2.94. Genomics BioSci & Tech Co's overall GF Score™ is 42/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Genomics BioSci & Tech Co (TPE:4195), the current PB Ratio is 2.36 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomics BioSci & Tech Co (TPE:4195) Overvalued in 2026?
Based on GuruFocus' analysis, Genomics BioSci & Tech Co stock appears to be undervalued.
The current stock price of NT$15.35 is trading 55.1% below its estimated GF Value™ of NT$34.15.
GuruFocus considers Genomics BioSci & Tech Co to be Possible Value Trap.
Key valuation signals for TPE:4195:
PB Ratio: 2.36 (28% below median its 10-year median of 3.29)
GF Value™: NT$34.15 vs. price of NT$15.35 (55.1% below fair value)
Industry Position: 19.7% below the Biotechnology median (#513 of 1225)
No single metric tells the full story. See the TPE:4195 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomics BioSci & Tech Co Ltd is a Taiwan based commercial genome sequencing company formed to develop medical genetic testing. The services of the company include Sanger sequence service, Synthesis Service and Genomic Service.
42GF Score
Get the complete analysis for TPE:4195
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:4195 has been successfully added to your 
